Home > Back to Publisher > Report Information

Prostate Cancer Therapeutics

Global Industry Analysts
April 1, 2009
739 Pages - SKU: GJOB2270518

Abstract Table of Contents Related Reports

Countries covered: Global

This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Millions. Analytics in the report specifically focuses on revenues generated from hormonal therapies.The report provides separate comprehensive analytics for US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2006 through 2015. The report profiles 138 companies including many key and niche players worldwide such as Abbott Laboratories, Æterna Zentaris Inc., ALZA Corporation, Amgen Inc., AstraZeneca PLC., Medimmune, LLC, Bristol-Myers Squibb Company, Cell Genesys Inc., Dendreon Corporation, EUSA Pharma, (USA) Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc., Immunomedics, Inc., Indevus Pharmaceuticals Inc., Novartis AG, OSI Pharmaceuticals, Inc., Paladin Labs Inc., Pfizer Inc., Progenics Pharmaceuticals, Inc., Sanofi-Aventis SA, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Product Definitions and Scope of Study; Radiation Therapy
II. EXECUTIVE SUMMARY: 1.Industry Overview; Key Prostate Cancer Drugs & Companies; Select Prostate Cancer Hormonal Therapy Drugs withYear of FDA Approval; Innovations in Drug Delivery: A Key Factor in ProductDifferentiation; Small Cap Companies: A Target of Private CapitalFinancing; Awareness Drives European Prostate Cancer TherapeuticsMarket; Table 3: New Cancer Cases Diagnosed in the USin 2007: Percentage Share by LeadingCancer Sites (includes correspondingGraph/Chart); Table 5: Male Population by Age Group in the USfor the year 2007 (includes correspondingGraph/Chart); Select FDA Approved Drugs for Palliative Treatmentof Advanced Prostate Cancer; Table 7: Five-Year Cancer Survival Rate Among USMales by Type - Prostate and Testis (1996-2002)(includes corresponding Graph/Chart); Molecular Imaging of Cancer: Critical in ImprovingPatient Outcomes; Multiple Drug Resistance; Notable Prostate Cancer Drug Failures in Phase IIIDevelopment; 2.Clinical Trials; Select Prostate Cancer Drugs Under Phase II/III Trialsby Leading Companies; Drugs in Pre-Clinical Stage; 3.Product Overview; Table 11: Cancer Death Rates in the US (2007):Percentage Breakdown by Cancer Type - Lung &Bronchus, Prostate, Colon & Rectum, Pancreas,Leukemia, and Others (includes correspondingGraph/Chart); Pituitary Gland; Prostate Cancer - A Primer; Table 14: New Incidences of Prostate Cancer (in ‘000) Worldwide for the years 2007 and 2008 (includes corresponding Graph/Chart); Table 15: Mortality Due to Prostate Cancer (in ‘000) Worldwide for the Years 2007 and 2008 (includes corresponding Graph/Chart); Table 16: Male Population (in Million) for the Year2007 for Select Regions (includes corresponding Graph/Chart); Screening/Detection of Prostate Cancer; Improved PSA Testing; Microbubble Ultrasound; Gleason Score; Genetic & Non-Genetic Factors; Table 17: Prostate Cancer Incidence/Mortality Rateby Race & Ethnicity in US, 1999-2003 (includescorresponding Graph/Chart); Prevention of Cancer; 4.Treatment Options for Prostate Cancer; LHRH Analogs; Anti-Androgens; Orchiectomy; Strategies to Enhance Hormonal Treatment; Treatment Procedure; Benefits of Brachytherapy; High Dose Rate (HDR) Brachytherapy; Whole Pelvic Radiation Therapy (WPRT); Risks Associated with Chemotherapy; Prostatectomy and Lymph Node Dissection; Cryosurgery; Benefits of IMRT; High Dose Radiation (HDR) Monotherapy; Recurrent Prostate Cancer; Recurrent Prostate Cancer Subsequent toRadiation Therapy; TCaxotere® (Docetaxel); Doxazosin, a Cytotoxic Drug for Prostate Cancer; Phase I Clinical Trials; Selective Endothelia A Receptor Antagonist -(SERA™); Other Select Targeted Therapies; 5.Drug Approvals and Clinical Studies; Cougar Conducts Phase I/II Clinical Trials on CB7630in Patients with Prostate Cancer; Bioponic Phytoceuticals Unveils Pre-Clinical Data onCurecumin™ for Prostate Cancer; Cell Therapeutics Reveals Phase 2 Clinical Trial Resultsof XYOTAX™ in Androgen Independent ProstateCancer Patients; Cleveland BioLabs to Initiate Phase II Clinical Trial forCuraxin in HRPC; Marshall Edwards Conducts Study on Phenoxodiolin Prostate Cancer; University of California’s Analyses Support Dendreon’sActive Cellular Immunotherapy; Panacea Pharmaceuticals Identifies Blood Protein forEarly Prostate Cancer Detection; Active Biotech Reveals Results of TASQ Phase I Studyfor Prostate Cancer; Balanced Intake of Omega-6 and Omega-3 Fatty AcidsFound to Reduce Prostate Cancer Growth; Protox Gains Clearance from FDA to Conduct Phase ITrial of PRX302; Biomira Announces Results of Stimuvax Phase2 Clinical Study; PNNL and IsoRay Develops Cesium-131 Seed forTreatment of Prostate Cancer; 6.Product Innovations/Introductions; Barr Unveils Generic Version of Proscar® Tablets; 7.Recent Industry Activity; Celera Enters into Licensing Agreement with Merck; GPC Biotech and Celgene Terminate Agreement forSatraplatin; Morphotek® Enters into Licensing Agreementwith NCI; Sirnaomics Extends Partnership with GRL to DevelopMulti-Targeted RNAi Therapeutic Products; Cougar Biotech Enters into an Agreement with US FDA; MacroArray Partners with Abbott on PCADM-1 Testfor Prostate Cancer; Sagemark Embarks on Radiation Therapy Venture; Core Oncology Completes Acquisition of Coloplast’sBrachytherapy Business; GSK Acquires Praecis Pharmaceuticals; MedMira Inks Agreement to Take Over Rights ofa New Marker Technology; Signet Enters into Agreement with AsymmetRx toDistribute ‘Prostate-63’ Tests; Progenics Pharmaceuticals Broadens Association withSeattle Genetics; Progenics Pharmaceuticals Acquires PSMA DevelopmentCompany; Indevus Enters into Agreement to Takeover Valera; Altana Divests Entire Stake in GPC Biotech; Valera and Spepharm Partner to Market Vantas, andSupprelin-LA; MediGene Introduces Prostate Cancer Drug in ItalianMarket; Protox Acquires PRX321 Cancer Program fromUS Public Health Service and Neurocrine; Paladin Signs an Agreement with Watson for Supply andSale of Trelstar®; Caprion and AstraZ eneca Enter into Collaboration; National Cancer Institute Enters into Agreementwith Illumina; 8.Focus on Select Global Players; Amgen Inc. (USA); Medimmune, LLC (USA); Dendreon Corporation (USA); F. Hoffmann-La Roche Ltd. (Switzerland); GlaxoSmithKline Plc (UK); Novartis AG (Switzerland); Paladin Labs Inc. (Canada); Sanofi-Aventis SA (France); 9.Global Market Perspective; Table 19: World 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Europe, and Rest ofWorld Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart)
III. MARKET: 1.The United States; Table 21: Male Population by Age Group in the USfor the Year 2007 (includes corresponding Graph/Chart); Market Challenges; Key Statistics; Table 26: New Cancer Cases Diagnosed in the US in 2007: Percentage Share by Leading Cancer Sites (includes corresponding Graph/Chart); Table 28: Mortality Due to Prostate Cancer in the US: Breakdown by Leading States for the Years 2007 and 2008 (includes corresponding Graph/Chart); Table 30: Comparison of Mortality Among African Americans and Whites by Cancer Type in the US,2000-2004 (includes corresponding Graph/Chart); Table 32: Five-Year Cancer Survival Rate Among US Males by Type - Prostate and Testis (1996-2002) (includes corresponding Graph/Chart); Table 34: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity in US, 1999-2003 (includes corresponding Graph/Chart); Product Launches; Select Players; B. Market Analytics; 2.Europe; Table 37: Mortality Due to Prostate Cancer inEurope: Breakdown by Region/ Country forthe Years 2007 and 2008 (In ‘000)(includes corresponding Graph/Chart); Product Launches; B. Market Analytics; Table 39: European 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest ofEurope Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart); 2a.France; Strategic Corporate Developments; Select Players; B. Market Analytics; 2b.Germany; GPC Biotech AG - A Major Player; 2c.Italy; B. Market Analytics; 2d.The United Kingdom; Product Launch; Select Players; B. Market Analytics; 2e.Spain; B. Market Analytics; 2f.Rest of Europe; Select Players; B. Market Analytics; 3.Rest of World; Table 48: Prostate Cancer Market in Canada (2008): New Cases and Deaths Due to Prostate Cancerby Age Group; Select Canadian Players; A Glance into Other Select Markets; Cancer Market in Asia; Malaysia; Cancer Market in Latin America; Table 52: Mortality Due to Prostate Cancer inLatin America: Breakdown by Region/ Countryfor the Years 2007 and 2008 (includescorresponding Graph/Chart); Strategic Corporate Developments; Select Players; B. Market Analytics
IV. COMPETITIVE LANDSCAPE: Total Companies Profiled: 138 (including Divisions/Subsidiaries - 153); Region/Country Players; The United States; Canada; Japan; Europe; Asia-Pacific (Excluding Japan)

More Global Men's Health Reports

Global Prostate Cancer Therapeutics Market (2010 - 2020) (Opportunity Analysis, Pipeline Assessment & Market Forecast) by MarketsandMarkets
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ...

Testosterone Replacement Therapy (TRT) by Global Industry Analysts
This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the ...

Erectile Dysfunction Drugs by Global Industry Analysts
This report analyzes the worldwide markets for Erectile Dysfunction Drugs in US$ Million. The report provides separate comprehensive analytics for US, Canada, Japan, Europe,and Rest ...

Disease and Therapy Review: Prostate Cancer by Timely Data Resources, Inc.
The Prostate Cancer Disease and Therapy Review provides an overview of the disease and related conditions, with incidence, prevalence and mortality numbers and percentages ...

The 2009 World Market Forecasts for Imported Rubber Sheath Contraceptives (Condoms) by Icon Group International, Inc.
This report was created for strategic planners, international marketing executives and export managers whose primary concern is the world market for rubber sheath contraceptives (condoms). ...

See all reports like this >>

Prostate Cancer Therapeutics

Share this report

Other tasks

Research Assistance

Related Markets

Men's Health Reports

Free Alert Me service